title: Preliminary report on activity and tolerability of epomediol, administered by intravenous infusion, in patients with chronic hepatopathies.
abstract: The therapeutic activity and tolerability of epomediol were studied in 28 patients with chronic hepatopathies. Treatment was continued, parenterally, for 10 days (400-600 mg once daily by intravenous infusion). Clinical parameters (headache, right hypochondrial pain, bitter taste in the mouth, asthenia and nausea) and hepatic function (transaminase, alkaline phosphatase and gamma-glutamyl transpeptidase) showed significant improvements. Clinical and systemic tolerabilities of epomediol were satisfactory.
authors.affiliation: Gastroenterology and Endoscopy Centre, Borgonovo Val Tidone Hospital, Piacenza, Italy.
authors.forename: F
authors.initials: F
authors.lastname: Mazzeo
authors.forename: D
authors.initials: D
authors.lastname: Bernocchi
authors.forename: C
authors.initials: C
authors.lastname: Cavalli
authors.forename: G
authors.initials: G
authors.lastname: Manini
mesh_terms: D000328:Adult; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003875:Drug Eruptions; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008107:Liver Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013729:Terpenes / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D019086:Bridged Bicyclo Compounds, Heterocyclic; D013729:Terpenes; C031365:epomediol